Cargando…

Autocrine EGF and TGF‐α promote primary and acquired resistance to ALK/c‐Met kinase inhibitors in non‐small‐cell lung cancer

Drug resistance severely limits the clinical therapeutic value of molecularly targeted drugs. Growth factors gain a tremendous amount of focus due to the ability to promote drug resistance in non‐small‐cell lung cancer (NSCLC). However, whether tumor cells themselves can mediate drug resistance by s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yueqin, Zhang, Yu, Chen, Ruiying, Tian, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801488/ https://www.ncbi.nlm.nih.gov/pubmed/36583451 http://dx.doi.org/10.1002/prp2.1047

Ejemplares similares

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
por: Dai, Yao, et al.
Publicado: (2012)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-α in human prostate cancer cells
por: Seth, D, et al.
Publicado: (1999)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

The Tetraspanin Cd9 Associates with Transmembrane TGF-α and Regulates TGF-α–Induced Egf Receptor Activation and Cell Proliferation
por: Shi, Wen, et al.
Publicado: (2000)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Firtina Karagonlar, Zeynep, et al.
Publicado: (2016)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020)

Isolation and Culture of Primary Mouse Retinal Pigment Epithelial (RPE) Cells with Rho-Kinase and TGFβR-1/ALK5 Inhibitor
por: Shen, Junhui, et al.
Publicado: (2017)

High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor
por: Auf, Gregor, et al.
Publicado: (2013)

Role of TGF-β in Survival of Phagocytizing Microglia: Autocrine Suppression of TNF-α Production and Oxidative Stress
por: Ryu, Keun-Young, et al.
Publicado: (2012)

Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions
por: Murphy, L O, et al.
Publicado: (2001)

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
por: Song, Zilan, et al.
Publicado: (2015)

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient
por: Hu, Yijuan, et al.
Publicado: (2019)

TGF-β1 autocrine signalling and enamel matrix components
por: Kobayashi-Kinoshita, Saeko, et al.
Publicado: (2016)

EGF, TGF-α and Amphiregulin Differently Regulate Endometrium-Derived Mesenchymal Stromal/Stem Cells
por: Kamentseva, Rimma Sergeevna, et al.
Publicado: (2023)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Phan, Ai N.H., et al.
Publicado: (2016)

Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
por: Phillip, Cornel Joseph, et al.
Publicado: (2013)

Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
por: Hu, Han, et al.
Publicado: (2022)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

EGF and TGF-β1 Effects on Thyroid Function
por: Mincione, Gabriella, et al.
Publicado: (2011)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain
por: Miller, Miles A., et al.
Publicado: (2015)

Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
por: Ji, Fujian, et al.
Publicado: (2015)

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
por: Papadakis, Andreas I, et al.
Publicado: (2015)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Roles of Autocrine TGF-β Receptor and Smad Signaling in Adipocyte Differentiation
por: Choy, Lisa, et al.
Publicado: (2000)

Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis
por: Ungefroren, Hendrik
Publicado: (2021)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture
por: Bergström, J D, et al.
Publicado: (1999)

Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
por: Phillip, Cornel Joseph, et al.
Publicado: (2016)

Autocrine expression of the epidermal growth factor receptor ligand heparin-binding EGF-like growth factor in cervical cancer
por: Schrevel, Marlies, et al.
Publicado: (2017)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6rvl7r258vos8114oqb2pva485